These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 26795112)

  • 1. Structural features underlying raloxifene's biophysical interaction with bone matrix.
    Bivi N; Hu H; Chavali B; Chalmers MJ; Reutter CT; Durst GL; Riley A; Sato M; Allen MR; Burr DB; Dodge JA
    Bioorg Med Chem; 2016 Feb; 24(4):759-67. PubMed ID: 26795112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.
    Overk CR; Peng KW; Asghodom RT; Kastrati I; Lantvit DD; Qin Z; Frasor J; Bolton JL; Thatcher GR
    ChemMedChem; 2007 Oct; 2(10):1520-6. PubMed ID: 17654759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity.
    Dodge JA; Lugar CW; Cho S; Short LL; Sato M; Yang NN; Spangle LA; Martin MJ; Phillips DL; Glasebrook AL; Osborne JJ; Frolik CA; Bryant HU
    J Steroid Biochem Mol Biol; 1997 Apr; 61(1-2):97-106. PubMed ID: 9328215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of SP500263, a novel selective estrogen receptor modulator, on bone, uterus, and serum cholesterol in the ovariectomized rat.
    Sutherland MK; Brady H; Gayo-Fung LM; Leisten J; Lipps SG; McKie JA; O'Leary E; Patnaik N; Anderson DW; Bhagwat SS; Stein B
    Calcif Tissue Int; 2003 Jun; 72(6):710-6. PubMed ID: 14563000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
    Grese TA; Pennington LD; Sluka JP; Adrian MD; Cole HW; Fuson TR; Magee DE; Phillips DL; Rowley ER; Shetler PK; Short LL; Venugopalan M; Yang NN; Sato M; Glasebrook AL; Bryant HU
    J Med Chem; 1998 Apr; 41(8):1272-83. PubMed ID: 9548817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
    Grese TA; Cho S; Finley DR; Godfrey AG; Jones CD; Lugar CW; Martin MJ; Matsumoto K; Pennington LD; Winter MA; Adrian MD; Cole HW; Magee DE; Phillips DL; Rowley ER; Short LL; Glasebrook AL; Bryant HU
    J Med Chem; 1997 Jan; 40(2):146-67. PubMed ID: 9003514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease.
    Newman CL; Creecy A; Granke M; Nyman JS; Tian N; Hammond MA; Wallace JM; Brown DM; Chen N; Moe SM; Allen MR
    Kidney Int; 2016 Jan; 89(1):95-104. PubMed ID: 26489025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women.
    Weinstein RS; Parfitt AM; Marcus R; Greenwald M; Crans G; Muchmore DB
    Osteoporos Int; 2003 Oct; 14(10):814-22. PubMed ID: 14610642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone cell-independent benefits of raloxifene on the skeleton: a novel mechanism for improving bone material properties.
    Gallant MA; Brown DM; Hammond M; Wallace JM; Du J; Deymier-Black AC; Almer JD; Stock SR; Allen MR; Burr DB
    Bone; 2014 Apr; 61():191-200. PubMed ID: 24468719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of combination treatment with alendronate and raloxifene on skeletal properties in a beagle dog model.
    Allen MR; McNerny E; Aref M; Organ JM; Newman CL; McGowan B; Jang T; Burr DB; Brown DM; Hammond M; Territo PR; Lin C; Persohn S; Jiang L; Riley AA; McCarthy BP; Hutchins GD; Wallace JM
    PLoS One; 2017; 12(8):e0181750. PubMed ID: 28793321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.
    Palkowitz AD; Glasebrook AL; Thrasher KJ; Hauser KL; Short LL; Phillips DL; Muehl BS; Sato M; Shetler PK; Cullinan GJ; Pell TR; Bryant HU
    J Med Chem; 1997 May; 40(10):1407-16. PubMed ID: 9154963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raloxifene, a selective estrogen receptor modulator, induces mitochondria-mediated apoptosis in human endometrial carcinoma cells.
    Morishima S; Shibata MA; Ohmichi M; Otsuki Y
    Med Mol Morphol; 2008 Sep; 41(3):132-8. PubMed ID: 18807138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacophore mapping of arylbenzothiophene derivatives for MCF cell inhibition using classical and 3D space modeling approaches.
    Mukherjee S; Nagar S; Mullick S; Mukherjee A; Saha A
    J Mol Graph Model; 2008 Jan; 26(5):884-92. PubMed ID: 17643328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new selective estrogen receptor modulator HMR-3339 fully corrects bone alterations induced by ovariectomy in adult rats.
    Ammann P; Bourrin S; Brunner F; Meyer JM; Clément-Lacroix P; Baron R; Gaillard M; Rizzoli R
    Bone; 2004 Jul; 35(1):153-61. PubMed ID: 15207751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel nonsteroidal selective estrogen receptor modulators. Carbon and heteroatom replacement of oxygen in the ethoxypiperidine region of raloxifene.
    Schmid CR; Sluka JP; Duke KM; Glasebrook AW
    Bioorg Med Chem Lett; 1999 Feb; 9(4):523-8. PubMed ID: 10098655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel hydroxyapatite biomaterial covalently linked to raloxifene.
    Meme L; Santarelli A; Marzo G; Emanuelli M; Nocini PF; Bertossi D; Putignano A; Dioguardi M; Lo Muzio L; Bambini F
    Int J Immunopathol Pharmacol; 2014; 27(3):437-44. PubMed ID: 25280036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo activation of gene transcription via oestrogen response elements by a raloxifene analogue.
    Engdahl C; Jochems C; Gustafsson JA; van der Saag PT; Carlsten H; Lagerquist MK
    J Endocrinol; 2009 Dec; 203(3):349-56. PubMed ID: 19752149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological activities of a novel selective oestrogen receptor modulator derived from raloxifene (Y134).
    Ning M; Zhou C; Weng J; Zhang S; Chen D; Yang C; Wang H; Ren J; Zhou L; Jin C; Wang MW
    Br J Pharmacol; 2007 Jan; 150(1):19-28. PubMed ID: 17115070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fourier transform infrared imaging analysis of cancellous bone in alendronate- and raloxifene-treated osteopenic sheep.
    Calton EF; Macleay J; Boskey AL
    Cells Tissues Organs; 2011; 194(2-4):302-6. PubMed ID: 21597262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The inhibitory effect of raloxifene on lipopolysaccharide-induced nitric oxide production in RAW264.7 cells is mediated through a ROS/p38 MAPK/CREB pathway to the up-regulation of heme oxygenase-1 independent of estrogen receptor.
    Lee SA; Kim EY; Jeon WK; Woo CH; Choe J; Han S; Kim BC
    Biochimie; 2011 Feb; 93(2):168-74. PubMed ID: 20888885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.